[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sstr2\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sstr2":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100616145","early-phase-1-clinical-application-of-68ga-fl-031-pet-in-the-diagnosis-and-staging-of-malignant-tumors-100616145",false,"NCT07301801","Clinical Application of 68Ga-FL-031 PET in the Diagnosis and Staging of Malignant Tumors","Inclusion Criteria:\n\n1. The subject or their legal representative is permitted to sign the informed consent form.\n2. The subject has committed themselves to adherence to the prescribed research procedures and to cooperation in the implementation of the entire study process.\n3. Adult patients (aged 18 years or older), irrespective of gender\n4. Patients with a clinical suspicion or confirmed diagnosis of small cell lung cancer, breast cancer, nasopharyngeal carcinoma, and other tumours (for which supporting evidence is provided in the form of serum-related tumour markers, ultrasound, CT, MRI and other image data, and histopathological examination)\n5. The patient is generally in good condition\n6. It is mutually agreed upon by all parties involved that the designated specimen shall be utilised for the purposes of this study.\n\nExclusion Criteria:\n\n1. The patient or his legal representative is unable or unwilling to sign the informed consent\n2. The patient is unable to cooperate with the implementation of the whole process research\n3. The patient has been diagnosed with acute systemic diseases and electrolyte disorders\n4. Pregnant women or lactating women, etc\n5. In the event of other circumstances being deemed by the investigator to be unsuitable for participation in the study, such patients must be excluded on the basis of their known intolerance to SSTR2 targeted substances.","ALL","18 Years",{"count":18,"type":19},10,"ESTIMATED","INTERVENTIONAL",[22],"EARLY_PHASE1","The project's objective is to recruit patients with clinically confirmed or suspected small cell lung cancer, breast cancer, nasopharyngeal carcinoma and other tumours for 68Ga-FL-031 PET imaging and 18F-FDG PET imaging. The histopathology of biopsy or surgical specimens was taken as the final diagnostic criteria, and the presence or absence of tumour lesions was confirmed by the aforementioned imaging. The location and nature of the lesion, and the presence or absence of metastasis, were then judged. The objective was to analyse and clarify the diagnostic efficacy of 68Ga-FL-031 PET imaging for the aforementioned malignant tumours. The objective of this study is to analyse the correlation between the 68Ga-FL-031 PET imaging tumour tissue uptake value and the tumour tissue immunohistochemical staining SSTR2 target expression.",[25,26,27],"Malignant Tumors","SSTR2","PET","RECRUITING","2025-12-11",{"date":31,"type":32},"2025-12-24","ACTUAL",{"date":34,"type":32},"2025-06-12",{"date":36,"type":19},"2026-09-30",{"name":38,"class":39},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":20,"phases":50,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":40},"100506391","68ga-fapi-lm3-petct-imaging-in-patients-with-fapsstr2-positive-disease-and-compared-with-18f-fdg-100506391","NCT05873777","68Ga-FAPI-LM3 PET\u002FCT Imaging in Patients With FAP\u002FSSTR2 Positive Disease and Compared With 18F-FDG","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order);\n* (ii) patients with suspected or newly diagnosed or previously malignant disease, with either FAP or SSTR2 positive expression (supporting evidence may include MRI, CT, and pathology report etc);\n* (iii) patients who had scheduled both 18F-FDG and 68Ga-FAPI-LM3 PET\u002FCT scans;\n* (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with non-malignant disease;\n* (ii) patients with pregnancy;\n* (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",true,{"count":49,"type":19},30,[51],"NA","As a new dual receptor (SSTR2 and FAP) targeting PET radiotracer, 68Ga-FAPI-LM3 is promising as an excellent imaging agent applicable to SSTR2 positive diseases. In this research, we investigate the safety, biodistribution and radiation dosimetry of 68Ga-FAPI-LM3 in healthy volunteers. Moreover, we evaluate the potential usefulness of 68Ga-FAPI-LM3 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of lesions in SSTR2 positive diseases, and compared with 18F-FDG PET\u002FCT.",[26,54,55],"FAP","Positron-Emission Tomography",[26,54,55],"2025-08-05",{"date":59,"type":32},"2025-08-08",{"date":61,"type":32},"2023-04-09",{"date":63,"type":19},"2025-12-31",{"name":65,"class":39},"The First Affiliated Hospital of Xiamen University"]